Skip to Main Content
The first stop for professional medicines advice

Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception

Published Last updated See all updates
Topics: LevonorgestrelPatient Group DirectionsReproductive healthTemplates

SPS PGD template for the insertion of the Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception.

Contents

  1. Provenance
  2. Templates available
  3. PGD template attachment
  4. Patient Group Directions, Templates, Reproductive health
  5. All PGD templates
  6. Update history

Provenance

Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.

August 2025 – note the Faculty of Sexual and Reproductive Healthcare (FSRH) has now changed its name to the College of Sexual and Reproductive Healthcare (CoSRH). Some web pages and CoSRH documents will continue to display the FSRH name; where you see FSRH, this refers to CoSRH. All weblinks are still active.

Templates available

Version 3.0 of this PGD template, valid from August 2026, has been published to allow organisations to undertake local governance processes in a timely manner.

Version 2.3 of this PGD template remains currently valid and will be removed from this page on its expiry (31st July 2026).

PGD template attachment

The template PGD is attached below to download and use in conjunction with our implementation advice (SPS page).

Patient Group Directions, Templates, Reproductive health

All PGD templates

National PGD, protocol and written instructions templates

National templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.

Update history

  1. Version 3.0 published
  1. Revised template due to minor clarifications following feedback.
  1. Version 2.1 template replaced with accessible version
  1. Republished
  2. Planned review detail added
  1. Information added regarding name change of FSRH to CoSRH
  1. Updated PGD template published. Statement added to off-label use section regarding extended use of 8 years for all 52mg products in line with FSRH statement. Uterine perforation added as exclusion.
  1. Updated added regarding FSRH 9th May published recommendation update
  1. Updated template published
  1. Detail regarding pending update added.
  1. Version 2.1 published - minor amendment
  1. V1 removed from website as expiring 31/7/23
  1. Title, URL and summary amended.
  1. New V2.0 template added
  1. Updated template attached - new product added
  1. Template republished with minor rewording
  1. Published